Lumentum vs McKesson Corporation — how do they compare? Lumentum trades at $1,105.23 (market cap $94.99B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: Lumentum and McKesson Corporation are close in size by market cap, and McKesson Corporation pays a 0.4% dividend while Lumentum pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lumentum for 4 Days and McKesson Corporation for 74 Days on average.
| LITE | MCK | |
|---|---|---|
Market Cap | $94.99B | $108.46B |
Volume | 4,855,776 | 712,607 |
Sector | Technology | Health |
52-Week High | $1.13K | $995.69 |
52-Week Low | $149.61 | $725.17 |
Typical Hold Time | 4 Days | 74 Days |
Enterprise Value | $93.92B | $115.00B |
Dividend Yield | — | 0.4% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →